Journal of medicinal chemistry, 2017-06-22, Vol.60 (12), p.5146-5161
The first-in-class soluble guanylate cyclase (sGC) stimulator riociguat was recently introduced as a novel treatment option for pulmonary hypertension. Despite its outstanding pharmacological profile, application of riociguat in other cardiovascular indications is limited by its short half-life, necessitating a three times daily dosing regimen. In our efforts to further optimize the compound class, we have uncovered interesting structure–activity relationships and were able to decrease oxidative metabolism significantly. These studies resulting in the discovery of once daily sGC stimulator vericiguat (compound 24, BAY 1021189), currently in phase 3 trials for chronic heart failure, are now reported.
Administration, Intravenous ; Administration, Oral ; Animals ; Blood Pressure - drug effects ; Chemistry Techniques, Synthetic ; Dogs ; Heart Failure - drug therapy ; Hepatocytes - drug effects ; Heterocyclic Compounds, 2-Ring - administration & dosage ; Heterocyclic Compounds, 2-Ring - chemistry ; Heterocyclic Compounds, 2-Ring - pharmacology ; Humans ; Male ; NG-Nitroarginine Methyl Ester - adverse effects ; Pyrimidines - administration & dosage ; Pyrimidines - chemistry ; Pyrimidines - pharmacology ; Rats, Transgenic ; Rats, Wistar ; Soluble Guanylyl Cyclase - genetics ; Soluble Guanylyl Cyclase - metabolism ; Structure-Activity Relationship
Hellenic Academic Libraries Link
Permalink to record
https://www.ncbi.nlm.nih.gov/pubmed/28557445$$D View this record in MEDLINE/PubMed